Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

Directive transparence : information réglementée

11/06/2021 09:00